Shares of Obseva SA (NASDAQ:OBSV) have been assigned a consensus recommendation of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $31.17.
Several equities analysts recently commented on the stock. Wedbush set a $34.00 price objective on shares of Obseva and gave the company a “buy” rating in a research note on Friday, January 25th. ValuEngine raised shares of Obseva from a “hold” rating to a “buy” rating in a research note on Tuesday, April 9th. HC Wainwright set a $44.00 price objective on shares of Obseva and gave the company a “buy” rating in a research note on Friday, January 4th. Zacks Investment Research cut shares of Obseva from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Finally, TheStreet cut shares of Obseva from a “c-” rating to a “d+” rating in a research note on Wednesday, January 16th.
A number of large investors have recently modified their holdings of the stock. Gables Capital Management Inc. purchased a new position in Obseva in the 4th quarter worth approximately $25,000. Barclays PLC grew its stake in Obseva by 331.1% in the 4th quarter. Barclays PLC now owns 10,118 shares of the company’s stock worth $128,000 after buying an additional 7,771 shares in the last quarter. United Services Automobile Association purchased a new position in Obseva in the 3rd quarter worth approximately $206,000. Geode Capital Management LLC purchased a new position in Obseva in the 4th quarter worth approximately $159,000. Finally, Jane Street Group LLC purchased a new position in Obseva in the 4th quarter worth approximately $218,000. 64.68% of the stock is owned by institutional investors.
Obseva (NASDAQ:OBSV) last posted its earnings results on Tuesday, March 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.01. On average, research analysts expect that Obseva will post -2.11 earnings per share for the current year.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
See Also: Consumer behavior in bull markets
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.